How frequently should an adult take vitamin D (cholecalciferol) 50,000 IU?

Vitamin D 50,000 IU Dosing Frequency

For treatment of vitamin D deficiency, take 50,000 IU once weekly for 8 weeks, then transition to maintenance dosing of 800–2,000 IU daily. 1

Treatment Phase (Correcting Deficiency)

The standard corrective regimen is 50,000 IU once weekly for 8 weeks when vitamin D deficiency is documented (25-OH-D <30 ng/mL). 1 This approach is specifically recommended in clinical guidelines for patients requiring repletion therapy.

• The FDA-approved product labeling for cholecalciferol 50,000 IU states "Take one (1) capsule each week, or as directed by your physician. Take with food." 2
• This weekly dosing for 8 weeks has been validated in clinical practice and achieves therapeutic 25-OH-D levels effectively. 1
• After the initial 8-week treatment period, you must switch to maintenance therapy to sustain adequate vitamin D levels. 1

Maintenance Phase (After Correction)

Following the 8-week treatment course, transition to 800–2,000 IU daily (or equivalent intermittent dosing such as 100,000 IU every 3 months). 1, 3

• Daily maintenance dosing is more physiologic and preferred over continued high-dose intermittent therapy. 1
• The rule of thumb: each 1,000 IU daily raises serum 25-OH-D by approximately 10 ng/mL, though individual responses vary. 1
• Compliance should be monitored, and doses adjusted if follow-up 25-OH-D levels remain insufficient. 1

Alternative Maintenance Regimens (If Daily Dosing Is Not Feasible)

If you cannot take daily supplements, bimonthly dosing of 50,000 IU (every 2 weeks) can maintain adequate vitamin D levels in some populations. 4

• Research shows that bimonthly 50,000 IU maintained 25-OH-D levels >75 nmol/L more effectively than monthly dosing. 4
• However, weekly dosing of 50,000 IU beyond the initial 8-week treatment period increases the risk of hypercalciuria (elevated urinary calcium), particularly in individuals with BMI >26 kg/m². 5
• Very high intermittent doses (such as 500,000 IU annually) have been associated with adverse outcomes and should be avoided. 1

Special Populations Requiring Higher Doses

Patients with obesity, malabsorption syndromes, liver disease, or those on medications affecting vitamin D metabolism may require higher maintenance doses (up to 7,000 IU daily or 30,000 IU weekly). 6

• For obese patients or those with malabsorption, 50,000 IU weekly may be continued longer than 8 weeks, but only under medical supervision with monitoring. 6
• In chronic kidney disease (CKD stage 3–4), weekly 50,000 IU for 12 weeks effectively corrects deficiency and may reduce PTH levels. 7

Safety Considerations

Hypercalcemia from vitamin D toxicity occurs only with daily intakes exceeding 100,000 IU or when 25-OH-D levels exceed 100 ng/mL. 1

• The upper safety threshold for serum 25-OH-D is 100 ng/mL; target range is 30–50 ng/mL for optimal health benefits. 1, 3
• Daily doses up to 10,000 IU for several months have not caused adverse events in healthy adults. 1
• Monitor 24-hour urinary calcium if using weekly 50,000 IU doses beyond the standard 8-week treatment, especially in overweight individuals. 5

Monitoring Recommendations

Measure serum 25-OH-D after at least 3 months of supplementation to assess adequacy. 1, 3

• For intermittent dosing, obtain the level immediately before the next scheduled dose. 1, 3
• Routine monitoring is not required for low-risk individuals on standard maintenance dosing (800–2,000 IU daily). 1, 3
• If 25-OH-D reaches 70–80 ng/mL, consider reducing supplementation, though this range remains safe. 1

Key Clinical Pitfalls to Avoid

• Do not continue 50,000 IU weekly indefinitely without monitoring—this increases hypercalciuria risk and provides no additional benefit beyond 8 weeks. 5
• Vitamin D₃ (cholecalciferol) is strongly preferred over vitamin D₂ (ergocalciferol) for intermittent dosing because it sustains serum levels longer. 1
• Always take vitamin D with food to enhance absorption, as it is a fat-soluble vitamin. 2
• The 50,000 IU dose is a treatment dose, not a maintenance dose—failure to transition to lower maintenance dosing after correction is a common error. 1